Anrukinzumab: Difference between revisions

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

@@ Line 1: / Line 1: @@
+{{Short description|Chemical compound}}
 {{Drugbox
+| Verifiedfields = changed
-| type              = mab
+| Watchedfields = changed
-| image             =
+| verifiedrevid = 458434000
-| alt               =
-| mab_type          = mab
+| type = mab
+| image =
-| source            = zu/o
+| alt =
-| target            = [[Interleukin 13|IL13]]
+| mab_type = mab
-| tradename         =
+| source = zu/o
-| Drugs.com         =
+| target = [[Interleukin 13|IL13]]
-| MedlinePlus       =
+| tradename =
-| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
+| Drugs.com =
-| pregnancy_US      = <!-- A / B            / C / D / X -->
+| MedlinePlus =
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
 | pregnancy_category=
-| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
+| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
 | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
 | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
 | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
-| legal_status      =
+| legal_status =
 | routes_of_administration =
-| bioavailability   =
+| bioavailability =
-| protein_bound     =
+| protein_bound =
-| metabolism        =
+| metabolism =
 | elimination_half-life =
-| excretion         =
+| excretion =
+| CAS_number_Ref = {{cascite|changed|??}}
-| CAS_number = <!-- blanked - oldvalue: 910649-32-0 -->
+| CAS_number = 910649-32-0
-| ATC_prefix        = none
+| ATC_prefix = none
-| ATC_suffix        =
+| ATC_suffix =
+| UNII_Ref = {{fdacite|correct|FDA}}
 | UNII = OU46IGC49F
-| PubChem           =
+| PubChem =
+| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
-| ChemSpiderID = NA
+| ChemSpiderID = none
-| DrugBank          =
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| C = 6452
+| DrugBank          =
-| H = 9954
-| N = 1714
+| C=6452 | H=9954 | N=1714 | O=2024 | S=46
-| O = 2024
-| S = 46
-| molecular_weight  = 145.4 kDa
 }}
-'''Anrukinzumab''' (IMA-638<ref name="IMA-638">{{cite web |url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing | year = 2008 |publisher = [[Wyeth]]|accessdate=November 19, 2008 |archiveurl = http://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate = June 12, 2008}}</ref>) is a humanized monoclonal antibody designed for the treatment of [[asthma]].<ref>[http://www.ama-assn.org/resources/doc/usan/anrukinzumab.pdf ''Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab''], [[American Medical Association]].</ref>
+'''Anrukinzumab''' (IMA-638<ref name="IMA-638">{{cite web|url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing |year=2008 |publisher=[[Wyeth]] |access-date=November 19, 2008 |archive-url=https://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archive-date=June 12, 2008 |url-status=dead }}</ref>) is a humanized monoclonal antibody designed for the treatment of [[asthma]].<ref>[http://www.ama-assn.org/resources/doc/usan/anrukinzumab.pdf ''Statement On A Nonproprietary Name Adopted By The USAN Council: Anrukinzumab''], [[American Medical Association]].</ref>
 Anrukinzumab was developed by [[Wyeth]].
@@ Line 44: / Line 47: @@
 == References ==
 <references/>
+{{Monoclonals for immune system}}
+{{Interleukin receptor modulators}}
+[[Category:Drugs developed by Wyeth]]
+[[Category:Abandoned drugs]]
 {{monoclonal-antibody-stub}}
-{{monoclonals for immune system}}
-[[Category:Wyeth]]